Psyence Biomedical Ltd. Common Shares (PBM)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 59/100 (HIGH), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 9.17% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
- Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
- Psyence BioMed Announces Strategic Ibogaine Investment
- Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
- Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
- Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
- Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Psyence Biomedical Ltd. Common Shares.
Full PBM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.